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Background: The combination of right sided portal vein ligation and hepatic parenchymal transection
thus inducing a hypertrophy of the left or left lateral sector is an innovative treatment option in treating
locally advanced hepatic tumors or hepatic metastases. The available published data regarding this
procedure is weak. We analyzed our own data regarding tumor recurrence and complications. The data
was then used to be critically analyzed using the available published literature. Methods: We treated
n ¼ 5 patients with an ALPPS (associating liver partition and portal vein ligation for staged hepatectomy).
The follow-up was 3 years. We analyzed the perioperative period, complications, mortality and onco-
logical survival rate. Results: In all patients (n ¼ 5) a R0-resection was achieved. N ¼ 1 patient died
postoperatively. N ¼ 1 patient died 6 month later due to a pulmonary embolism. N ¼ 3 patients had a
tumor recurrence within 6 months. Conclusion: Selected patients can be successfully treated by ALPPS
in terms of an R0-resection. However, risk of tumor recurrence and rate of complications are high.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
In patients with extensive hepatic metastases or a large primary
cancer of the liver, R0-resection is the only treatment option that
gives a possibility of cure. Currently, the two-stage-hepatectomy by
combining portal vein ligation with in-situ split of liver (ALPPS)
followed by repaid hypertrophy of left lateral section of liver to
allow subsequent resection is a hot topic in liver surgery [1]. This
technique has beenwell-described and enables liver resection to beance with the declaration of
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by Elsevier Ltd. All rights reservedcarried out for patients with advanced hepatic malignancies with
high risks of developing postoperative hepatic failure/insufﬁciency
due to inadequate future liver remnants [2e4]. Different techniques
have been described to induce hypertrophy of hepatic tissues for
these patients. This can be achieved through transcatheter embo-
lization or alternatively through surgical portal vein ligation [5,6].
The aim of our study is to evaluate our data, especially on onco-
logical results of ALPPS, and its possible complications.2. Material and methods
We analyzed and evaluated the data of our patients who un-
derwent ALPPS. In the past 5 years, there were more than 350
hepatic resections in our university hospital. 5 of these resections
were ALPPS. The necessity of an ALPPS procedure was based on the.
Table 2
Surgical procedure and time interval.
Patient Operation Time-interval
1 Extended right hemihepatectomy 14 d
2 Segmentectomy 4,5,8 þ Subsegmentectomy 3 21 d
3 Extended right hemihepatectomy 14 d
4 Extended right hemihepatectomy
þ atypical left lateral resection Sg. 2,3
14 d
5 Extended right hemihepatectomy 19 d
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volume of the future liver remnant. The patients were followed-up
regularly after the operation. We did not carry out routine 3D liver
reconstruction.
The surgical technique conformed with the technique as
described in the published literature [7,8]. Laparotomy was via an
inverted “L” incision, and the liver was fully mobilized. After ruling
out peritoneal carcinomatosis and intraabdominal metastases,
intraoperative ultrasound was performed. Lymphadenectomy of
the hepatoduodenal ligament then followed. The right liver was
then mobilized from the inferior vena cava, and the hepatic artery,
portal vein and common hepatic duct were prepared. The right
portal vein distal to the bifurcationwas then dissected and sutured,
followed by hepatic parenchymal transection. If there was tumor in
the future liver remnant, an atypical hepatic resection was carried
out. To prevent post-operative adhesions, omentoplasty was per-
formed in 2 patients. CT was done 7e10 days after the initial sur-
gery to evaluate the degree of liver hypertrophy in the future liver
remnant. If the volume of the future liver remnant was considered
sufﬁcient, the second stage surgery was carried out (extended liver
resection after ligation and division of the previously prepared
structures including the right hepatic artery, right and middle he-
patic veins and right hepatic duct).3. Results
Five patients were treated by ALPPS (Table 1) and in all the
patients a R0-resection was achieved (Table 2). One patient died
postoperatively due to hemorrhagic shock. This patient was a
member of “Jehova's Witness” who refused blood transfusion. In
two patients, recurrence of liver metastases occurred within 8
weeks after ALPPS. In one of these patients who had a primary
gastrointestinal tumor (GIST) of the small bowel, hepatic metas-
tases occurred after only 6 months (Table 2). One patient who was
tumor free, died 8 months after ALPPS due to pulmonary embolism
following an orthopedic operation. All patients experienced surgi-
cal related complications (Table 3). The time between the ﬁrst and
the second surgery was 14 days in four patients and 21 days in one
patient.
Regarding the surgical techniques three patients received a
“classical” ALPPs procedure. In one patient a catheter guided
transhepatic embolization of the left portal veinwith vascular plugs
and microspheres (700e900 mm) was performed. Because of
insufﬁcient hypertrophy of the left hepatic section, a two-staged
operation was added. In another patient a three-staged procedure
was performed. During the ﬁrst stage, subsegmental resection of
segment 3 with dissection of the portal vein branch supplying
segment 1 and 4, transection of the hepatic parenchyma between
the left lateral section and segment 4 were performed. During the
second stage the tumors were resected by resection of segments 4,
5, 6 and atypical segmental resection of segment 8. This was
necessary because hypertrophy of the left lateral section was not
sufﬁcient. After hypertrophy of the left-lateral section and theTable 1
Patient data.
Patient Sex Age Primary tumor Tumor stage Chemotherapy
1 M 38 GIST small bowel Imatinib/sunitinib
2 W 72 ICC pT2a pN1 Mo
L1 V0 G2
None
3 M 65 Barrett-Ca ypT2 ypN2 R0 6 cycles Cisplatin/5-FU
4 M 52 Rectal cancer pT2 pN0 pM1 14 cycles FOLFIRI þ
Bevacizumab
5 M 71 Colon cancer pT4 pN0 M1 Noneremnant right liver the remaining right liver was resected in a third
stage, thus leaving the left lateral section (Sg. 2,3).
Renal insufﬁciency needing dialysis did not occur in any patient.
Liver insufﬁciency occurred in 2 patients who presented with
edema and hyperbilirubinema. The median hospital stay was 52
days (Figs. 1 and 2).
4. Discussion
R0-resection is a treatment option aiming at cure for patients
suffering from colorectal livermetastases or a large primary hepatic
cancer. The limiting factor is the volume of the future liver remnant
after resection. The phenomenon of hypertrophy of the liver is long
known. This can be achieved by embolization or ligation of the right
or left portal blood ﬂow [9]. However, these procedures also run the
risk of tumor progression between the time of embolization and
resection [10,11].
With ALPPS, the time taken between inducing hypertrophy and
resection can be reduced to 10e14 days when compared with 6
weeks in portal vein embolization. This may reduce the risk of
further metastatic disease [4,12]. The rate of liver hypertrophy for
ALPPS (the combination of ligation of the right portal branch, he-
patic parenchymal transection and devascularisation of segment
IV) is superior to portal vein occlusion or embolization [4]. In
concordance with the data available in the published literature we
were able to induce rapid hypertrophy to the left lateral section and
were able to perform resection in 14 days in four patients, and no
patient died from hepatic failure.
In two out of ﬁve patients, early liver recurrence (within 8
weeks) was detected. In the paper by Oldhafer et al. [7], one patient
developed new metastases after 6 month. One of our patients had
underlying gastrointestinal tumor. A probable explanation for early
tumor recurrence is in the primary tumor (GIST compared to
adenocarcinoma). The possibility of tumor progression with in-
duction of liver hypertrophy has already been discussed [13e15].
Oldhafer et al. did not only describe recurrence of hepatic metas-
tases but also described distant metastases. A possible hypothesis is
that the induction of liver hypertrophy is due to release of growth
factors which increase the chance of intrahepatic/extrahepatic
metastases. In addition, immunosuppression due to the extensive
surgical resection triggers growth and tumor spread. There is no
available data to suggest whether adjuvant chemotherapy is useful
or not.Table 3
Complications and oncological outcome.
Patient Dindo-Clavien
classiﬁcation
Hospital stay Mortality Recurrence
1 III 30 d N 6 month later
2 V 34 d, death Y
3 II d 69 d N 4 weeks later
4 II d 91 d N 8 weeks later
5 II d 37 d N n
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Fig. 2. Post-operative serum creatinine levels.
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Fig. 1. Post-operative serum bilirubine levels.
A. Troja et al. / International Journal of Surgery 12 (2014) 1020e10221022The available literature on ALPPS shows that patients have to be
carefully selected [16].
To what extent patients with colorectal hepatic metastases and
or a large primary hepatic tumor could proﬁt from ALPPS cannot be
certain at this point [17].
5. Conclusion
In conclusion the analysis of our data supported early recur-
rence and metastases after ALPPS. The underlying mechanism is
still not fully understood. R0-resection in selected patients by
ALPPS is possible. It is crucial to ﬁnd out what patients can beneﬁt
from this extensive procedure.
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